Japan’s Pharma Industry Seen Swallowing Tax Pill In Q2 And Then Getting Better
This article was originally published in The Pink Sheet Daily
Executive Summary
The healthy prospects for pharmaceutical sales in Japan are unlikely to be severely dented in the second quarter by a rate increase in the country’s consumption tax. Instead further steady growth is anticipated after record figures were posted last year.